142 related articles for article (PubMed ID: 2181621)
1. Endoscopic findings in the stomach and duodenum after treatment with enteric-coated and plain naproxen tablets in healthy subjects.
Oddsson E; Gudjonsson H; Thjodleifsson B
Scand J Gastroenterol; 1990 Mar; 25(3):231-4. PubMed ID: 2181621
[TBL] [Abstract][Full Text] [Related]
2. Naproxen-associated gastroduodenal toxicity: enteric coated granules versus plain tablets.
Aabakken L; Ugstad M; Gamst ON; Winther R; Osnes M
Eur J Rheumatol Inflamm; 1992; 12(2):43-8. PubMed ID: 1364939
[TBL] [Abstract][Full Text] [Related]
3. Gastroscopic findings after treatment with enteric-coated and plain naproxen tablets in healthy subjects.
Trondstad RI; Aadland E; Holler T; Olaussen B
Scand J Gastroenterol; 1985 Mar; 20(2):239-42. PubMed ID: 3887555
[TBL] [Abstract][Full Text] [Related]
4. Morning stiffness and nightime pain in ankylosing spondylitis. A comparison between enteric-coated and plain naproxen tablets.
Johnsen V; Brun JG; Fjeld E; Hansen K; Sydnes OA; Ugstad MB
Eur J Rheumatol Inflamm; 1992; 12(2):37-42. PubMed ID: 1364937
[TBL] [Abstract][Full Text] [Related]
5. Enteric coated naproxen tablets.
Gamst ON
Eur J Rheumatol Inflamm; 1992; 12(2):5-8. PubMed ID: 1364940
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the gastrointestinal side effects of naproxen formulated as plain tablets, enteric-coated tablets, or enteric-coated granules in capsules.
Aabakken L; Bjørnbeth BA; Hofstad B; Olaussen B; Larsen S; Osnes M
Scand J Gastroenterol Suppl; 1989; 163():65-73. PubMed ID: 2814364
[TBL] [Abstract][Full Text] [Related]
7. Enteric-coated and plain naproxen tablets in osteoarthritis; tolerability and efficacy.
Lehn OF; Jensen ON; Andersen LA; Christensen KA; Solheim L; Barslev J; Mjølstad W; Wiig G; Ibfelt HH; Kjønniksen T
Eur J Rheumatol Inflamm; 1992; 12(2):31-6. PubMed ID: 1364936
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
Goldstein JL; Aisenberg J; Lanza F; Schwartz H; Sands GH; Berger MF; Pan S
Clin Ther; 2006 Mar; 28(3):340-51. PubMed ID: 16750449
[TBL] [Abstract][Full Text] [Related]
9. Enteric coated naproxen; a double blind trial comparing the tolerance of enteric coated and standard formulations.
Huskisson EC; Bernstein RM; Coppock JS; Davies PG; Doyle DV; Platt PR; Scott DL; Witherington RH; Wojtulewski JA
Eur J Rheumatol Inflamm; 1992; 12(2):27-30. PubMed ID: 1364935
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients.
Bianchi Porro G; Lazzaroni M; Petrillo M
Am J Gastroenterol; 1997 Apr; 92(4):663-7. PubMed ID: 9128319
[TBL] [Abstract][Full Text] [Related]
11. An endoscopic comparison of gastroduodenal injury with over-the-counter doses of ketoprofen and acetaminophen.
Lanza FL; Codispoti JR; Nelson EB
Am J Gastroenterol; 1998 Jul; 93(7):1051-4. PubMed ID: 9672328
[TBL] [Abstract][Full Text] [Related]
12. NSAID-associated gastrointestinal damage: methodological considerations and a review of the experience with enteric coated naproxen.
Aabakken L
Eur J Rheumatol Inflamm; 1992; 12(2):9-20. PubMed ID: 1364941
[TBL] [Abstract][Full Text] [Related]
13. Steady-state pharmacokinetics of enteric-coated naproxen tablets compared with standard naproxen tablets.
Jung D; Schwartz KE
Clin Ther; 1994; 16(6):923-9. PubMed ID: 7697688
[TBL] [Abstract][Full Text] [Related]
14. Gastroduodenal lesions induced by naproxen. An endoscopic evaluation of regional differences and natural course.
Aabakken L; Osnes M
Scand J Gastroenterol; 1990 Dec; 25(12):1215-22. PubMed ID: 2274742
[TBL] [Abstract][Full Text] [Related]
15. A comparison of enteric-coated aspirin granules with plain and buffered aspirin: a report of two studies.
Petroski D
Am J Gastroenterol; 1986 Jan; 81(1):26-8. PubMed ID: 3942122
[TBL] [Abstract][Full Text] [Related]
16. Prostaglandin E2 content in residual gastric juice reflects endoscopic damage to the gastric mucosa after naproxen sodium administration.
Sarosiek J; Marcinkiewicz M; Parolisi S; Peura DA
Am J Gastroenterol; 1996 May; 91(5):873-8. PubMed ID: 8633574
[TBL] [Abstract][Full Text] [Related]
17. Duration of morning stiffness in rheumatic patients after medication with enteric-coated and plain naproxen tablets.
Johnsen V; Bjerkhoel F; Bjørneboe O; Børresen B; Finstad R; Hansen K; Moen F
Scand J Rheumatol; 1986; 15(1):37-40. PubMed ID: 3515526
[TBL] [Abstract][Full Text] [Related]
18. Comparison of gastrointestinal blood loss induced by cloximate in two formulations and by naproxen.
Rameis H; Hitzenberger G; Liem KS; Hulkenberg-Tromp D
Int J Clin Pharmacol Ther Toxicol; 1984 Feb; 22(2):96-8. PubMed ID: 6365812
[TBL] [Abstract][Full Text] [Related]
19. Gastroduodenal lesions associated with two different piroxicam formulations. An endoscopic comparison.
Aabakken L; Olaussen B; Mowinckel P; Osnes M
Scand J Gastroenterol; 1992 Dec; 27(12):1049-54. PubMed ID: 1475622
[TBL] [Abstract][Full Text] [Related]
20. Dose-effect comparisons of the CINOD AZD3582 and naproxen on upper gastrointestinal tract mucosal injury in healthy subjects.
Wilder-Smith CH; Jonzon B; Fornstedt-Wallin B; Hedman A; Karlsson P
Scand J Gastroenterol; 2006 Mar; 41(3):264-73. PubMed ID: 16497612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
